Rotavirus vaccines for global use: What are the remaining issues and challenges?

Jiang, Baoming; Patel, Manish; Parashar, Umesh D.

doi:10.4161/hv.6.5.11180

Cited by 4 publications

(6 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite of all success stories, both vaccines suffer from common limitations. Results from clinical trials proved that both vaccines are less effective in Latin America, Africa, and Asia where the demand of an effective rotavirus vaccine is always high [92]. Studies have revealed that immunogenicity of both Rotarix™ and RotaTeq ® ranged from 60% in Latin America, 76% South Africa, and less than 50% in Bangladesh, Vietnam, and Malawi, while the value was above 90% in Europe [83,91,[93][94][95][96].…”

Section: Rotavirus Vaccine: Success and Limitations Seem To Be The Two Sides Of The Same Coinmentioning

confidence: 99%

“…Research towards the development of an effective inactivated rotavirus vaccine is underway around the world [126]. Based on the scientific evidences, inactivated vaccines have advantages over oral vaccines, and therefore, it is now more rational to introduce an inactivated rotavirus vaccine [92,127]. Inactivated vaccine is free from risk factors such as breastfeeding, gastric acid, microbiota in gut, as well as EE, and will not cause any intussusception [92,126].…”

Section: Inactivated Rotavirus Vaccine Best Alternative To Present Solution: Why and How?mentioning

confidence: 99%

“…Based on the scientific evidences, inactivated vaccines have advantages over oral vaccines, and therefore, it is now more rational to introduce an inactivated rotavirus vaccine [92,127]. Inactivated vaccine is free from risk factors such as breastfeeding, gastric acid, microbiota in gut, as well as EE, and will not cause any intussusception [92,126]. Inactivated vaccine can also overcome the problem associated with lower efficacy of the existing rotavirus vaccine.…”

Section: Inactivated Rotavirus Vaccine Best Alternative To Present Solution: Why and How?mentioning

confidence: 99%

See 2 more Smart Citations

Rotavirus epidemiology and vaccine demand: considering Bangladesh chapter through the book of global disease burden

Mahmud-Al-Rafat¹,

Muktadir²,

Muktadir³

et al. 2017

Infection

View full text Add to dashboard Cite

Currently, two live attenuated vaccines are available throughout the world. Many countries have included rotavirus vaccines in national immunization program to reduce the disease burden. However, due to low efficacy of the available vaccines, satisfactory outcome has not yet been achieved in developing countries such as Bangladesh. Poor economic, public health, treatment, and sanitation status of the low-income countries necessitate the need for the most effective rotavirus vaccines. Therefore, the present scenario demands the development of a highly effective rotavirus vaccine. In this regard, inactivated rotavirus vaccine concept holds much promise for reducing the current disease burden. Recent advancements in developing an inactivated rotavirus vaccine indicate a significant progress towards disease prophylaxis and control.

show abstract

Section: Rotavirus Vaccine: Success and Limitations Seem To Be The Two Sides Of The Same Coinmentioning

confidence: 99%

Section: Inactivated Rotavirus Vaccine Best Alternative To Present Solution: Why and How?mentioning

confidence: 99%

Section: Inactivated Rotavirus Vaccine Best Alternative To Present Solution: Why and How?mentioning

confidence: 99%

See 1 more Smart Citation

Rotavirus epidemiology and vaccine demand: considering Bangladesh chapter through the book of global disease burden

Mahmud-Al-Rafat¹,

Muktadir²,

Muktadir³

et al. 2017

Infection

View full text Add to dashboard Cite

show abstract

“…In this sense, mucosal immunization is mandatory to determine if a protective immune response against rotavirus can be elicited, by testing this VP6-expressing vector on the mouse model of rotavirus infection [34–36]. Furthermore, research on inoculation routes as well as immunization protocols will bring insight into this bacterial display platform strategy, suggesting a safer alternative to attenuated viral pathogens, which is the current strategy for human immunization against rotavirus [5, 7]. Additionally, these bacterial vectors expressing heterologous proteins are economical to produce and have a great potential for large-scale use of the NICE system [37].…”

Section: Resultsmentioning

confidence: 99%

“…The rotavirus diarrhea is associated with a high mortality rate, particularly in developing countries, as well as to a considerable economic burden. These facts have led to an extensive research in rotavirus vaccinology to prevent its morbidity and mortality [5–7]. …”

Section: Introductionmentioning

confidence: 99%

Antigenicity and Immunogenicity of Rotavirus VP6 Protein Expressed on the Surface ofLactococcus lactis

Esteban

Temprana

Argüelles

et al. 2013

BioMed Research International

View full text Add to dashboard Cite

Group A rotaviruses are the major etiologic agents of acute gastroenteritis worldwide in children and young animals. Among its structural proteins, VP6 is the most immunogenic and is highly conserved within this group. Lactococcus lactis is a food-grade, Gram-positive, and nonpathogenic lactic acid bacteria that has already been explored as a mucosal delivery system of heterologous antigens. In this work, the nisin-controlled expression system was used to display the VP6 protein at the cell surface of L. lactis. Conditions for optimal gene expression were established by testing different nisin concentrations, cell density at induction, and incubation times after induction. Cytoplasmic and cell wall protein extracts were analyzed by Western blot and surface expression was confirmed by flow cytometry. Both analysis provided evidence that VP6 was efficiently expressed and displayed on the cell surface of L. lactis. Furthermore, the humoral response of mice immunized with recombinant L. lactis was evaluated and the displayed recombinant VP6 protein proved to be immunogenic. In conclusion, this is the first report of displaying VP6 protein on the surface of L. lactis to induce a specific immune response against rotavirus. These results provide the basis for further evaluation of this VP6-displaying L. lactis as a mucosal delivery vector in a mouse model of rotavirus infection.

show abstract

Human rotavirus virus-like particle vaccines evaluated in a neonatal gnotobiotic pig model of human rotavirus disease

Azevedo

Vlasova²,

Saif³

2013

Expert Review of Vaccines

View full text Add to dashboard Cite

The authors discuss here rotavirus-like particle vaccines as an alternative approach to oral live-attenuated rotavirus vaccine and their efficacy in a gnotobiotic pig model. Rotavirus virus-like particles (VLPs) were evaluated in different doses, and routes of administration, and combined with live-attenuated virus and adjuvants. A VLP vaccine composed of rotavirus VP2 and VP6 was immunogenic in gnotobiotic pigs when inoculated intranasally; however, this vaccine failed to confer protection. A combination of oral attenuated human rotavirus and intranasal 2/6VLP vaccines conferred immunogenicity, partial protection against a human rotavirus challenge and induced IFN-γ-producing T cells in the ileum of pigs with similar frequencies to human rotavirus infection. Vaccination through a combination of mucosal inductive sites and live-attenuated vaccine combined with VLP vaccines was the most effective regimen, compared with the use of a single route or a single vaccine alone. However, if formulated with neutralizing antigens, VLP vaccines may constitute a better approach in a high maternal antibody scenario.

show abstract

Rotavirus vaccines for global use: What are the remaining issues and challenges?

Cited by 4 publications

References 15 publications

Rotavirus epidemiology and vaccine demand: considering Bangladesh chapter through the book of global disease burden

Rotavirus epidemiology and vaccine demand: considering Bangladesh chapter through the book of global disease burden

Antigenicity and Immunogenicity of Rotavirus VP6 Protein Expressed on the Surface ofLactococcus lactis

Human rotavirus virus-like particle vaccines evaluated in a neonatal gnotobiotic pig model of human rotavirus disease

Contact Info

Product

Resources

About